Production (Stage)
Verve Therapeutics, Inc.
VERV
$4.36
-$0.02-0.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 479.03% | 154.28% | 120.24% | 219.73% | 305.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 479.03% | 154.28% | 120.24% | 219.73% | 305.63% |
| Cost of Revenue | 12.57% | 17.60% | 14.10% | 7.88% | 2.69% |
| Gross Profit | 49.67% | -0.72% | -5.97% | 1.94% | 6.62% |
| SG&A Expenses | 7.00% | 14.80% | 18.41% | 8.43% | 12.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.31% | 17.02% | 15.01% | 8.00% | 4.82% |
| Operating Income | 35.55% | -3.93% | -8.74% | -0.44% | 2.43% |
| Income Before Tax | 36.35% | -3.40% | -9.49% | 7.56% | 6.44% |
| Income Tax Expenses | -25.47% | 128.13% | 55.22% | -62.50% | -- |
| Earnings from Continuing Operations | 36.32% | -3.48% | -9.56% | 7.74% | 6.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.32% | -3.48% | -9.56% | 7.74% | 6.23% |
| EBIT | 35.55% | -3.93% | -8.74% | -0.44% | 2.43% |
| EBITDA | 36.75% | -3.69% | -8.45% | 0.13% | 3.36% |
| EPS Basic | 40.38% | 17.02% | 18.17% | 32.14% | 30.31% |
| Normalized Basic EPS | 40.40% | 17.09% | 18.22% | 32.00% | 30.45% |
| EPS Diluted | 40.38% | 17.02% | 18.17% | 32.14% | 30.31% |
| Normalized Diluted EPS | 40.40% | 17.09% | 18.22% | 32.00% | 30.45% |
| Average Basic Shares Outstanding | 6.81% | 24.69% | 33.89% | 35.95% | 34.55% |
| Average Diluted Shares Outstanding | 6.81% | 24.69% | 33.89% | 35.95% | 34.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |